GlassScriptPhysician profile
Chip D Holbrook
NPI 1962546192
$2,821.50
in general payments reported to CMS, 2019-2025
28 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $224 · 2021: $299 · 2022: $612 · 2023: $194 · 2024: $600 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $393.02 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $364.68 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $249.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.02 | 2019-2025 | Jardiance |
| Amgen INC. | $124.88 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $111.02 | 2021-2024 | Capvaxive, Gardasil 9, Vaqta |
| Avanir Pharmaceuticals, INC. | $103.57 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $87.21 | 2022-2023 | Seglentis |
| Abbvie INC. | $75.09 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $64.58 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $61.86 | 2023-2024 | Voquezna |
| Mylan Specialty L.P. | $61.00 | 2020-2021 | |
| Axsome Therapeutics, INC. | $44.62 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $39.16 | 2025 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $34.97 | 2024-2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $30.68 | 2023-2024 | Inpefa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.31 | 2025 | Caplyta |
| Abbott Laboratories | $30.14 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.21 | 2021 | |
| Shield Therapeutics INC | $22.89 | 2023 | Accrufer |
| Sunovion Pharmaceuticals INC. | $22.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.33 | 2019-2021 | |
| Purdue Pharma L.P. | $18.82 | 2025 | Nalmefene Hydrochloride |
| Bayer Healthcare Pharmaceuticals INC. | $17.40 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.18 | 2023 | Quviviq |
| Lucid Diagnostics INC. | $14.83 | 2024 | |
| Pfizer INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chip Holbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.